

ZOGENIX

Zogenix to Release Fourth Quarter and Full-Year 2016 Financial Results and Host Conference Call and Webcast on March 9

March 2, 2017

EMERYVILLE, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2016, after the market close, and will host a corporate update conference call and webcast on Thursday, March 9th, at 4:30 PM Eastern Time.

Thursday, March 9th @ 4:30 PM Eastern Time/1:30 PM Pacific Time

Toll Free: 877-675-4750

International: 719-325-4867

Conference ID: 1061121

Webcast: <http://public.viavid.com/index.php?id=122985>

Replays, available through March 23, 2017:

Domestic: 844-512-2921

International: 412-317-6671

Replay PIN: 1061121

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

CONTACT:

Investors: Andrew McDonald

Founding Partner, LifeSci Advisors LLC

646-597-6987 | Andrew@lifesciadvisors.com

 Zogenix

Zogenix, Inc.